Work

A Framework for Treatment Interruption and Restart: Clinical Analyses, Recovery Dynamics, and Mechanistic Simulations

Year: 2026
Type: preprint
Abstract: Treatment interruption and restart require assessment of patient recovery, delayed toxicity, and disease response. This study presents a focused application of Longitudinal Optimization of Global Outcomes and Strategies (LOGOS), to three methodological tasks: a) evaluating predictive information available before restart, b) comparing delayed effects across complete dosing schedules with specified administered amounts and follow-up, and c) examining how recovery mechanisms alter modeled disease control and injury. Exploratory clinical analyses were kept separate from pharmacokinetic/pharmacodynamic (PK/PD) and hypothetical simulations. Among 132 recorded mercaptopurine restart episodes from 73 patients, pre-restart absolute neutrophil count (ANC) improved internal prediction of the minimum ANC recorded within 14 days after restart (patient-weighted leave-one-patient-out RMSE reduction: 7.33%). Palbociclib PK/PD simulations yielded different ANC nadirs despite equal total administered amounts and follow-up. Hypothetical mechanistic simulations identified conditions under which cycling improved modeled disease control while reducing injury. Abiraterone analyses described PSA trajectories during biomarker-guided interruption and restart but did not establish restored drug sensitivity. The LOGOS’s methodological contribution refers to structure restart-time prediction and full-course schedule comparison under explicit conditions, not to introduce new PK/PD equations. Potential clinical applications include post-restart monitoring support and comparative treatment planning; clinical benefit remains unproven and requires external validation and prospective evaluation.
Language: English
Open Access status: green
OpenAlex ID: W7226023325
Cites:
Cited by:
Related to: 9